Non-muscle-invasive bladder cancer (NMIBC) is characterised by a high risk of recurrence when performing only a transurethral resection of the bladder (TURB). Intravesical instillations are performed postoperatively to decrease the rate of recurrence. The standard agents currently used are Mitomycin-C (MMC) or bacillus Calmette-Guérin (BCG). In order to further enhance the efficacy of the adjuvant treatments and/or diminish their side effects, alternative treatments are studied. Intravesical MMC combined with hyperthermia could be an interesting alternative active treatment for intermediate- and possibly high-risk NMIBC, and has been investigated in the past years. Two methods for achieving hyperthermia are described and presently evaluated: heating the bladder wall by the mean of an intravesical microwave generator (Synergo(®)) and heating the MMC before it is instilled in the bladder (Combat BRS(®)).
Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie. 2016 [Epub ahead of print]
Service d'urologie, CHU Bicêtre, 78, rue du Général-Leclerc, 94270 Le-Kremlin-Bicêtre, France. Electronic address: .